Access the “What This Means” segment here BOSTON and LONDON – June 25, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune …
Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2025
AGM VOTING RESULTS (FORM 8-K) NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2025 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL …
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical …
